Welcome to our dedicated page for RLFTD news (Ticker: RLFTD), a resource for investors and traders seeking the latest updates and insights on RLFTD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RLFTD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RLFTD's position in the market.
Relief Therapeutics Holding SA and NRx Pharmaceuticals have reached settlement agreements to resolve litigation. Within the next 30 days, NRx will transfer assets used in aviptadil development to Relief. Relief will gain exclusive rights to develop and commercialize aviptadil while continuing the Right to Try Program for two years. They will pay NRx milestone payments for successful product approvals and royalties up to $30 million based on sales. NRx will refrain from future competition in aviptadil development. The success of aviptadil commercialization is uncertain.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. have extended the stay of their pending litigation until November 11, 2022. They are progressing in negotiations for a settlement; however, no final agreements have been reached, introducing uncertainty about the outcome.
Relief specializes in developing treatments for rare diseases, with products including PKU GOLIKE and ongoing projects like aviptadil and APR-TD011, which has FDA Orphan Drug Designation. The company is listed on the SIX Swiss Exchange under symbol RLF and OTCQB under RLFTF and RLFTD.
Relief Therapeutics, a Swiss biopharmaceutical company, has announced promising six-month stability data for a new formulation of RLF-100 (aviptadil) that shows high purity across various temperatures. This data supports the commercialization of RLF-100, which targets serious lung diseases like pulmonary sarcoidosis and ARDS. Relief plans to initiate a Phase 2b study in 2023 for pulmonary sarcoidosis. The company has also filed a provisional patent application for this formulation, underlining its potential clinical and commercial value.